EXTENDED REPORT

Sex differences in gout epidemiology: evaluation and treatment

L R Harrold, R A Yood, T R Mikuls, S E Andrade, J Davis, J Fuller, K A Chan, D Roblin, M A Raebel, A Von Worley, R Platt, K G Saag

Ann Rheum Dis 2006;65:1368–1372. doi: 10.1136/ard.2006.051649

See end of article for authors' affiliations

Correspondence to:
L R Harrold, Department of
Medicine, University of
Massachusetts Medical
School, 55 Lake Avenue
North, Worcester, MA
01655, USA;
HarroldL@ummc.org

Accepted 10 April 2006
Published Online First
27 April 2006

Background: Little is known about the characteristics, evaluation and treatment of women with gout.

Objective: To examine the epidemiological differences and differences in treatment between men and women in a large patient population.

Methods: The data from approximately 1.4 million people who were members of seven managed care plans in the USA for at least 1 year between 1 January 1999 and 31 December 2003 were examined. Adult members who had pharmacy benefits and at least two ambulatory claims specifying a diagnosis of gout were identified. In addition, men and women who were new users of urate-lowering drugs (ULDs) were identified to assess adherence with recommended surveillance of serum urate levels within 6 months of initiating urate-lowering treatment.

Results: A total of 6133 people (4975 men and 1158 women) with two or more International Classification of Disease-9 codes for gout were identified. As compared with men with gout, women were older (mean age 70 (SD 13) v 58 (SD 14), $p < 0.001$) and had comorbidities and received diuretics more often (77% v 40%; $p < 0.001$). Only 37% of new users of urate-lowering treatment had appropriate surveillance of serum urate levels post-initiation of urate-lowering treatment. After controlling for age, comorbidities, gout treatments, number of ULD dispensings and health plan, women were more likely (odds ratio 1.36, 95% confidence interval 1.11 to 1.67) to receive the recommended serum urate level testing.

Conclusions: Women with gout were older, had greater comorbidities and more often used diuretics and received appropriate surveillance of serum urate levels, suggesting that the factors leading to gout as well as monitoring of treatment are very different in women and men.

Gout is a common inflammatory arthropathy affecting up to 5 million Americans, and the prevalence is rising.¹ Although gout has been studied for centuries, only a handful of studies have examined sex differences in gout epidemiology and treatment, and they included relatively small numbers of women with gout.^{2–8} Most textbooks describe gout as “predominantly a disease of men”.⁹ Also, much of the recent gout research has focused solely on men and has not included women.^{4–6} However, among those >60 years of age, the incidence of gout in women may be equivalent to men.⁷

Over the past decade there have been several demographic and treatment pattern changes that could potentially change or magnify sex differences in gout epidemiology. These changes include the ageing of the population,¹⁰ increased use of thiazide diuretics as the preferred treatment for hypertension^{11–12} and increased prevalence of obesity^{13–14} and metabolic syndrome¹⁵—all of which are risk factors for gout. Because women live longer and have a higher prevalence of hypertension after the age of 50 years than men,¹⁶ gout will probably be of increasing concern in older women. Therefore, further investigation into the potential sex differences in the presentation, evaluation and treatment of gout are warranted.

In our study, we examined differences between men and women with gout in terms of risk factors (eg, age, comorbidities and diuretic use), evaluation and treatment patterns, and monitoring of serum urate levels after initiating a urate-lowering drug (ULD) using the administrative databases of seven health maintenance organisations (HMOs). The limited literature on sex differences in the

clinical characteristics of adults with gout suggests that women with gout tend to be older and have a higher prevalence of comorbid disease.^{2–3–17} To the best of our knowledge, no population-based studies have examined how the risk factors of gout differ between women and men and whether such differences influence the evaluation and treatment of gout. We hypothesised that although the drug and disease factors contributing to the development of gout differ between women and men, the evaluation and treatment of the condition would be similar.

METHODS

Setting

The study population included members from seven health plans that are part of the HMO Research Network Center for Education and Research on Therapeutics.¹⁸ The HMO Research Network Center for Education and Research on Therapeutics member organisations include staff, group, network, independent practice association and mixed model HMOs that provided healthcare for approximately 7 million people in more than 1000 practice sites in the year 2000. We chose a representative sample of roughly 200 000 members, from each of the seven HMOs that participated, for inclusion into the dataset. The sampling scheme and demographic distribution of this population have been described elsewhere.¹⁹ The dataset had computerised information on use of

Abbreviations: CPT, current procedural terminology; HMO, health maintenance organisation; ICD, International Classification of Disease; NSAIDs, non-steroidal anti-inflammatory drugs; ULD, urate-lowering drug

Table 1 Baseline characteristics of the study population*

	Men		Women		p Value
	n	% or SD	n	% or SD	
Totals	4975	81%	1158	19%	
Age (mean years)	58	14	70	12	<0.001
Mean and median number of encounters for gout	2.7, 2	3	2.9, 2	2	<0.001
Gout-associated comorbidities					
Hypertension	2833	57%	939	81%	<0.001
Dyslipidaemia	1894	38%	491	42%	<0.01
Coronary heart disease	943	19%	287	25%	<0.001
Peripheral arterial disease	202	4%	77	7%	<0.001
Diabetes mellitus	866	17%	350	30%	<0.001
Nephrolithiasis	153	3%	27	2%	0.18
Renal insufficiency	485	10%	204	18%	<0.001
Renal failure	308	6%	143	12%	<0.001
Drugs that can trigger or exacerbate gout (receipt of ≥ 1 prescription)					
Thiazide diuretics	1487	30%	636	55%	<0.001
All diuretics	2003	40%	897	77%	<0.001

* p Values represent comparisons between men and women for the variables listed.

healthcare services, including membership information, pharmacy dispensing data, and selected hospital and ambulatory diagnoses and procedures, including laboratory tests from 1 January 1999 to 31 December 2003. Institutional review boards at each participating organisation approved this study.

Study population and design

We identified members from the dataset who met the criteria for enrolment into the "gout cohort". Criteria for inclusion in the gout cohort were as follows: ≥ 19 years of age at the time of the first gout diagnosis, two or more ambulatory visits at least 30 days apart associated with an International Classification of Disease-9 (ICD-9) code for a gout diagnosis (ICD-9 codes 274.0, 274.1, 274.8, 274.9) and continuous enrolment in the health plan with drug coverage during the period 6 months before and 12 months after the first gout diagnosis. Risk factors for gout (comorbidities and diuretic use) and relevant laboratory testing and treatments were identified during this period using the claims data. Age, as of first gout diagnosis, and sex were ascertained from the demographic data.

From the gout cohort, we identified new users of ULDs. A new user was defined as a cohort member who received no dispensing of a ULD (allopurinol, probenecid or sulfinpyrazone) during the 6 months before the gout diagnosis but was subsequently dispensed a ULD. In this subset of gout cohort patients, the same demographic and healthcare usage information was gathered as described above during the period 6 months before and 6 months after the first dispensing of a ULD. Age at the time of the first dispensing of ULD was used for the subsequent analyses.

We ascertained the presence of comorbidities from the ICD-9 diagnosis codes associated with ambulatory care. Comorbidities of interest included coronary heart disease, diabetes mellitus, dyslipidaemia, hypertension, nephrolithiasis, peripheral arterial disease, renal insufficiency and renal failure (table AI). Laboratory testing, including measurement of serum urate levels, 24-h urine tests for uric acid secretion and synovial fluid analyses, and joint or bursal diagnostic aspirations and therapeutic injections were ascertained using current procedural terminology (CPT) codes (table AII). Aspirations and injections of joints and bursae have the same CPT code; we were thus unable to differentiate between them. Drug usage was identified by determining dispensings using national drug codes for the following drug classes: diuretics (thiazide, potassium-sparing, loop and others),

non-acetylated salicylates, both cyclooxygenase selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, colchicine, uricosuric drugs, allopurinol and glucocorticoids.

Analyses

Differences between men and women were evaluated using t test or the Wilcoxon rank sum test for continuous variables and χ^2 test or Fisher's exact test for categorical variables. Differences between women and men in the evaluation and treatment of gout were assessed using multivariable logistic regression, adjusting for age, total number of encounters with a gout diagnosis, comorbidities, use of diuretics and health plan. Odds ratio (OR) and 95% confidence intervals (CI) were estimated.

We also compared new users of ULDs who received serum urate monitoring within 6 months after initiating treatment with those who did not, for demographic characteristics (including age and sex), comorbidities, use of diuretics and treatment practices. The 6-month time frame for serum urate monitoring after initiation of a ULD was chosen based on the gout quality-of-care indicators developed by Mikuls *et al.*²⁰ Multivariable logistic regression was used to assess the strength of association between sex and receipt of the recommended surveillance of serum urate levels. We controlled for number of encounters associated with a gout diagnosis, as women may be more likely to receive laboratory monitoring because they had more healthcare encounters for gout than men. OR and 95% CI were estimated. Analyses were conducted using SAS V.9.1.

RESULTS

Table 1 shows the characteristics of the study population. As compared with men with gout, women with gout were older and more often had hypertension, dyslipidaemia, coronary heart disease, diabetes mellitus, peripheral arterial disease, renal insufficiency and renal failure. Use of diuretics was almost twofold greater in women than in men (thiazide diuretics 55% v 30%; $p < 0.001$ and any diuretic 77% v 40%; $p < 0.001$). The proportion of women with gout who had serum urate levels tested during the period under study was similar to that observed in men (table 2); however, after controlling for age, number of encounters with a gout diagnosis, comorbidities, use of diuretics and health plan, women were more likely to have this test carried out. Although 24-h urine tests for uric acid excretion were carried out in a minority of patients, after multivariable adjustment

Table 2 Differences between women and men with gout in diagnostic evaluation and surveillance during the period under study

Test	Men		Women		Unadjusted	Adjusted*
	n	%	n	%	OR (95% CI)	OR (95% CI)
Serum urate	3327	67	795	69	1.09 (0.95 to 1.25)	1.20 (1.02 to 1.40)
24-h urine for uric acid excretion	245	5	67	6	1.19 (0.90 to 1.57)	1.40 (1.04 to 1.90)
Synovial fluid cell count	226	5	34	3	0.64 (0.44 to 0.92)	0.56 (0.38 to 0.83)
Synovial crystal analysis	245	5	32	2	0.56 (0.38 to 0.80)	0.49 (0.34 to 0.72)
Diagnostic aspirations or therapeutic joint or bursal injections	771	15	217	19	1.26 (1.07 to 1.49)	1.10 (0.91 to 1.32)

*Adjusted for age, number of encounters with a gout diagnosis, gout-associated comorbidities (including hypertension, dyslipidaemia, coronary heart disease, peripheral arterial disease, diabetes mellitus, nephrolithiasis, renal insufficiency and renal failure), use of diuretics and health plan.

women were more likely to undergo this test. In adjusted analyses, women were less likely to have synovial fluid cell counts and synovial crystal analysis carried out, but no less likely to receive diagnostic aspirations and therapeutic injections.

Women were considerably more likely than men to receive cyclooxygenase selective NSAIDs, non-acetylated salicylates, narcotics and glucocorticoids (table 3). Interestingly, the proportion of men and women who received allopurinol was identical (56%). However, after accounting for confounding variables, women were considerably less likely to receive this drug.

Only 37% of new users of ULDs had serum urate levels assessed within 6 months of starting a ULD. Even among people who received six or more dispensings of a ULD in the 6-month period under study, only 45% received the recommended surveillance. After controlling for age, comorbidities, treatments for gout, number of visits associated with a diagnosis of gout, number of ULD dispensings and health plan, women were more likely (OR 1.36, 95% CI 1.11 to 1.67) to receive surveillance of serum urate level (table 4).

DISCUSSION

Our study is the first to examine, from a population-based perspective, sex differences in the population characteristics, evaluation and treatment of gout. The differences between women and men with gout are striking, as the women are about a decade older, have more associated comorbidities and are more likely to be taking diuretics. Over the past 20 years there have been only four small studies specifically examining sex differences in clinical characteristics of gout, none of which were population based.^{2 3 17 21} Lally *et al*² in 1986 compared the clinical cases of 23 women with gout with 75 men with crystal-proven gout. As compared with the men, the women were older, more likely to be receiving diuretics and more often had renal insufficiency. Similarly, Puig *et al*³

in 1991 compared the clinical features of 37 women with gout with 2002 men with gout. Here again, the women developed gout at a later age, had more associated comorbidities and received diuretics more often. Both Meyers and Monteagudo¹⁷ and DeSouza *et al*²¹ examined the medical records of women and men with gout and found that women were more likely to have tophi or polyarticular disease at presentation and upper extremity joint involvement, suggesting potentially that in women the diagnosis of gout may be delayed or the condition may be confused with other forms of arthritis.

Our findings as well as those of others^{2 3 17 21} indicate that the risk factors for gout in women are different from those in men. For example, renal disease and receipt of diuretics, both of which predispose to gout, were more common in women. Current recommendations calling for the use of thiazide diuretics as the preferred treatment for hypertension¹¹ may have important implications in terms of gout frequency, particularly among older women. Hypertension, also an independent risk factor for hyperuricaemia and gout, is more common in women >50 years than in men of the same age.¹⁶

It was surprising that after adjustment for age, comorbidities and use of diuretics, women were less likely to receive allopurinol than men. In addition, it was interesting that women in our study received glucocorticoids and narcotics more often than men, possibly suggesting they had more severe episodes, greater chronicity to their gout or intolerance to other gout treatments; however, these drugs are not specific for gout and could have been used for other conditions. Further investigation into the management of gout in women and men is needed to assess whether treatment differences reflect appropriate care based on differences in the clinical spectrum of gout.

As shown in our study, substantial proportions of people who initiate treatment with ULDs do not receive surveillance of serum urate levels after initiation of the drug.

Table 3 Treatment differences between women and men with gout

Treatments for gout (receipt of ≥ 1 prescription of the following)	Men		Women		Unadjusted	Adjusted*
	n	%	n	%	OR (95% CI)	OR (95% CI)
Non-selective NSAID	3791	76	798	69	0.69 (0.60 to 0.80)	0.95 (0.80 to 1.11)
Selective NSAID	249	5	111	10	2.01 (1.59 to 2.54)	1.68 (1.29 to 2.18)
Non-acetylated salicylates	191	4	114	10	2.74 (2.15 to 3.48)	1.99 (1.54 to 2.58)
Narcotics	2336	47	698	60	1.71 (1.50 to 1.95)	1.44 (1.24 to 1.67)
Colchicine	2203	44	567	49	1.21 (1.06 to 1.37)	1.07 (0.93 to 1.24)
Uricosuric drug	201	4	57	5	1.23 (0.91 to 1.66)	1.16 (0.84 to 1.61)
Allopurinol	2792	56	647	56	0.99 (0.87 to 1.13)	0.78 (0.67 to 0.90)
Glucocorticoids	1631	33	488	42	1.49 (1.31 to 1.70)	1.30 (1.12 to 1.50)

NSAID, non-steroidal anti-inflammatory drug.

*Adjusted for age, number of encounters with a gout diagnosis, gout-associated comorbidities (including hypertension, dyslipidaemia, coronary heart disease, peripheral arterial disease, diabetes mellitus, nephrolithiasis, renal insufficiency and renal failure), use of diuretics and health plan.

Table 4 Associations between surveillance of serum urate levels within 6 months of initiating a urate-lowering drug (ULD) and sex, comorbidities, gout treatments and number of ULD dispensings

Factor	Unadjusted		Adjusted*	
	OR	95% CI	OR	95% CI
Sex (men referent)	1.49	1.23 to 1.80	1.36	1.11 to 1.67
Dyslipidaemia	1.65	1.40 to 1.93	1.42	1.19 to 1.68
Renal insufficiency	1.97	1.57 to 2.48	1.74	1.35 to 2.23
Colchicine use	1.80	1.54 to 2.10	1.61	1.36 to 1.90
Glucocorticoid use	1.82	1.52 to 2.17	1.56	1.29 to 1.89
Selective NSAID use	2.35	1.67 to 3.51	1.76	1.15 to 2.70
Non-selective NSAID use	1.39	1.19 to 1.63	1.62	1.37 to 1.92
ULD (number of dispensings; one dispensing referent)				
Two	1.42	1.07 to 1.88	1.65	1.23 to 2.22
Three	1.72	1.32 to 2.24	2.15	1.63 to 2.84
Four	1.95	1.48 to 2.56	2.25	1.68 to 3.00
Five	2.46	1.79 to 3.38	2.27	1.63 to 3.18
Six or more	2.42	1.84 to 3.19	2.37	1.77 to 3.18

NSAID, non-steroidal anti-inflammatory drug; ULD, urate-lowering drug.

*Controlled for individual Health maintenance organizations as well as the above-mentioned variables.

Interestingly, women were more likely than men to receive appropriate monitoring after controlling for age, comorbidities, gout treatments, number of ULD dispensings and health plan. Although beyond the scope of this study, potential reasons for these differences could include greater vigilance by doctors when treating women with gout owing to a greater number of associated comorbidities and associated drugs, more overall healthcare encounters by women resulting in greater opportunities for monitoring, or better adherence by women with physician recommendations. Because we cannot account for serum urate tests ordered but not carried out, it is not possible to separate physician non-adherence with ordering a recommended laboratory test from patient non-adherence with obtaining the test.

An important strength of this study is that it includes a large population of patients with two or more diagnoses of gout at least 30 days apart, thus increasing the likelihood that these people were truly considered to have gout by the treating doctor. In addition, the patient sample is derived from seven health plans across the USA and thus includes a diversity of people. Limitations include lack of validation of diagnostic and procedure claims data, although any bias that occurred would be non-differential between women and men. In addition, we cannot verify that the drugs examined were prescribed for gout. We were unable to assess the clinical implications of adherence and non-adherence with the recommended surveillance of serum urate levels in terms of provider response to serum urate levels, efficacy of urate-lowering treatment and clinical outcomes. Lastly, our results may not be generalisable to other health plans or other systems of healthcare delivery. At a minimum, these results are probably generalisable to at least 1 in 4 (24.6%) residents in the USA who are enrolled in HMOs.²²

In summary, this is the first population-based study examining sex differences in gout epidemiology, evaluation and treatment. The characteristics of women and men with gout are strikingly different, suggesting different risk factors for the condition. Of note, women were less likely to receive allopurinol after controlling for confounders using multi-variable logistic regression. Lastly, women with gout were also more likely to receive the recommended surveillance of serum urate levels within the first 6 months after ULD initiation. This work suggests further investigation into quality of care for gout to ensure that both women and men with gout receive the recommended evaluation and treatment.

ACKNOWLEDGEMENTS

We thank Hassan Fouayzi, MS, Jim Livingston, MS, and Parker Pettus, MS, for their assistance with data management and computer programming. We thank Kimberly Lane, MPH, and Kimberly Hill, MS, for project coordination. We acknowledge the project managers and programmers from each of the organisations.

Authors' affiliations

L R Harrold, R A Yood, S E Andrade, J Davis, J Fuller, Meyers Primary Care Institute, University of Massachusetts Medical School and Fallon Foundation, Worcester, Massachusetts, USA

T R Mikuls, University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska, USA

K A Chan, Channing Laboratory and Harvard School of Public Health, Boston, Massachusetts

D Roblin, Kaiser Permanente Georgia, Atlanta, Georgia, USA

M A Raebel, Kaiser Permanente Colorado, Denver, Colorado, USA

A Von Worley, Lovelace Clinic Foundation, Albuquerque, New Mexico, USA

R Platt, Harvard Pilgrim Health Care, Boston, Massachusetts

K G Saag, University of Alabama, Birmingham, Alabama, USA

Funding: This work was supported by grants from TAP Pharmaceuticals and from the Agency for Healthcare Research and Quality (HS10391 and HS10389).

Competing interests: None.

REFERENCES

- Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC.** The association between gout and nephrolithiasis in men: the health professionals' follow-up study. *Kidney Int* 2003;**64**:1022–6.
- Lally EV, Ho G Jr, Kaplan SR.** The clinical spectrum of gouty arthritis in women. *Arch Intern Med* 1986;**146**:2221–5.
- Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, et al.** Female gout. Clinical spectrum and uric acid metabolism. *Arch Intern Med* 1991;**151**:726–32.
- Choi HK, Atkinson K, Karlson EW, Curhan G.** Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. *Arch Intern Med* 2005;**165**:742–8.
- Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G.** Alcohol intake and risk of incident gout in men: a prospective study. *Lancet* 2004;**363**:1277–81.
- Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G.** Purine-rich foods, dairy and protein intake, and the risk of gout in men. *N Engl J Med* 2004;**350**:1093–103.
- Agudelo C, Wise C.** Crystal-associated arthritis. *Clin Geriatr Med* 1998;**14**:495–513.
- Rott KT, Agudelo CA.** Gout. *JAMA* 2003;**289**:2857–60.
- Terkeltaub RA.** Gout: Epidemiology, pathology and pathogenesis. In: Klippel JH, Crofford L, Stone JH, et al. *Primer on the rheumatic disease*. 12th edn. Atlanta: Arthritis Foundation, 2001:307–12.
- Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R.** Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. *J Rheumatol* 2004;**31**:1582–7.

- 11 **ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group.** Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2000;**283**:1967–75.
- 12 **Chobanian AV,** Bakris GL, Black HR, Cushman WC, Green LA, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA* 2003;**289**:2560–72.
- 13 **Lin KC,** Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. *J Rheumatol* 2000;**27**:1501–5.
- 14 **St Onge MP,** Keller KL, Heymsfield SB. Changes in childhood food consumption patterns: a cause for concern in light of increasing body weights. *Am J Clin Nutr* 2003;**78**:1068–73.
- 15 **Bieber JD,** Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. *Arthritis Rheum* 2004;**50**:2400–14.
- 16 **Reyes D,** Lew SQ, Kimmel PL. Gender differences in hypertension and kidney disease. *Med Clin North Am* 2005;**89**:613–30.
- 17 **Meyers OL,** Montegudo FS. A comparison of gout in men and women. A 10-year experience. *S Afr Med J* 1986;**70**:721–3.
- 18 **Platt R,** Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. *Pharmacoepidemiol Drug Saf* 2001;**10**:373–7.
- 19 **Chan KA.** Development of a multipurpose dataset to evaluate potential medication errors in ambulatory setting. In: Henriksen K, Battles JB, Marks ES, Lewin DI, eds. *Advances in patient safety: from research to implementation*. Vol 2. Rockville, MD: Agency for Healthcare Research and Quality, 2005.
- 20 **Mikuls TR,** MacLean CH, Olivieri JJ, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators in gout management. *Arthritis Rheum* 2004;**50**:937–43.
- 21 **Souza AWS,** Fernandes V, Ferrari AJL. Female gout: clinical and laboratory features. *J Rheumatol* 2005;**32**:2186–8.
- 22 **National Center for Health Statistics.** *Health, United States 2004 with chartbook on trends in the health of Americans*. Hyattsville, MD: 2004, (Health maintenance organizations (HMOs) and enrollment, according to model type, geographic region, and federal program. USA:1976–2003). <http://www.cdc.gov/nchs/data/has/has04trend.pdf#tables> (accessed 18 Nov 2005).

APPENDIX

International classification of diseases and current procedural terminology codes for the various comorbidities analysed in women with gout.

Table A1 Ambulatory diagnostic codes of interest used to identify relevant conditions

Diagnosis	ICD-9 codes
Hypertension	
Malignant	401.0x
Benign	401.1x
Unspecific	401.9x
Secondary	405.xx
Dyslipidaemia	
Hyperlipidaemia	272.1-9x
Hypercholesterolaemia	272.0x
Coronary heart disease	
Angina	413.xx
Bypass grafting	414.xx
Cardiovascular disease	429.2x
Acute myocardial infarction	410.xx
Old myocardial infarction	412.xx
Unstable angina	411.1x
Peripheral arterial disease	
Peripheral vascular disease	443.9x
Diabetes mellitus	
All forms of diabetes	250.xx
Nephrolithiasis	
Calculi of kidney and ureter	592.xx
Uric acid stones	274.11
Renal insufficiency	
Renal insufficiency	593.9x
Renal failure	
Acute renal failure	584.xx
Chronic renal failure	585.xx
Renal failure unspecified	586.xx

ICD, International Classification of Diseases.

Table AII Ambulatory procedures codes of interest

Procedure	CPT code
Diagnostic/therapeutic procedures	
Aspiration or injections of bursa/joint	20600–20610
Laboratory tests	
Arthritis panel	80072
Serum urate (uric acid)	84550
24-h urine for uric acid secretion	84560
Synovial fluid analysis	
Cell count and differential	89050, 89051
Crystal analysis	89060
Gram stain and culture	87070

CPT, current procedural terminology.